RXRX vs TEM
RXRX and TEM side by side — valuation & fundamentals (public data).
Key statistics
| Metric | RXRXRECURSION PHARMACEUTICALS, INC. | TEMTempus AI, Inc. |
|---|---|---|
| Market cap | $1.74B | $12.55M |
| P/B | — | 0.03 |
| P/S | 22.8x | 0.0x |
| Revenue | — | $1.43B(TTM) |
| Revenue growth (YoY) | 26.9% | 83.4% |
| Net income | — | -$254.40M(TTM) |
| Earnings growth (YoY) | -39.1% | 65.3% |
| EPS, diluted | — | $-1.44(TTM) |
| EBIT margin | -867.9% | -19.9% |
| ROE | -70.5% | -55.1% |
| ROIC | -175.2% | — |
| 1y total return | -34.1% | -19.6% |
Figures from SEC filings · for reference only · not investment advice
Growth of $10,000: RXRX vs TEM
| Metric | RXRX | TEM |
|---|---|---|
| End value | $3.4K | $17.4K |
| Total return | -65.5% | +73.8% |
| CAGR | -37.6% | +27.8% |
| Volatility | 82.6% | 97.5% |
| Sharpe | -0.22 | 0.68 |
| Sortino | -0.33 | 1.10 |
| Max drawdown | -73.9% | -59.8% |
Based on 565 common trading days, 2024-06-14 → 2026-09-16 · risk-free 4.14% (current short-Treasury, held constant)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)